{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aranesp", "query": { "intervention": "Aranesp" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 62, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aranesp&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T04:07:28.030Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05265325", "title": "A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Anemia" ], "interventions": [ { "name": "AND017 capsules TIW", "type": "DRUG" }, { "name": "AND017 capsules QW", "type": "DRUG" }, { "name": "epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kind Pharmaceuticals LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2023-05-03", "completion_date": "2024-04-25", "has_results": false, "last_update_posted_date": "2024-06-28", "last_synced_at": "2026-10-02T04:07:28.030Z", "location_count": 10, "location_summary": "Pine Bluff, Arkansas • Riverside, California • Lone Tree, Colorado + 5 more", "locations": [ { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Riverside", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Dalton", "state": "Georgia" }, { "city": "Gallup", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT05265325" }, { "nct_id": "NCT00436748", "title": "Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Chronic Kidney Disease", "Kidney Disease" ], "interventions": [ { "name": "Darbepoetin Alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 116, "start_date": "2008-09-16", "completion_date": "2014-03-03", "has_results": true, "last_update_posted_date": "2022-11-29", "last_synced_at": "2026-10-02T04:07:28.030Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436748" }, { "nct_id": "NCT00598442", "title": "Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Renal Failure", "Chronic Kidney Disease", "Anemia" ], "interventions": [ { "name": "peginesatide", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Affymax", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 493, "start_date": "2007-11", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2013-02-12", "last_synced_at": "2026-10-02T04:07:28.030Z", "location_count": 42, "location_summary": "Phoenix, Arizona • Fayetteville, Arkansas • Fountain Valley, California + 38 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Granada Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00598442" }, { "nct_id": "NCT00355407", "title": "Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "Darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2006-06", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2009-03-13", "last_synced_at": "2026-10-02T04:07:28.030Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00355407" }, { "nct_id": "NCT03457701", "title": "Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaemia" ], "interventions": [ { "name": "Daprodustat", "type": "DRUG" }, { "name": "rhEPO", "type": "DRUG" }, { "name": "Ferrous sulfate containing the stable iron isotope (57Fe)", "type": "DRUG" }, { "name": "Ferrous sulfate containing the stable iron isotope (58Fe)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2019-07-30", "completion_date": "2022-07-05", "has_results": true, "last_update_posted_date": "2024-03-27", "last_synced_at": "2026-10-02T04:07:28.030Z", "location_count": 3, "location_summary": "Fort Worth, Texas • Lufkin, Texas • San Antonio, Texas", "locations": [ { "city": "Fort Worth", "state": "Texas" }, { "city": "Lufkin", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03457701" }, { "nct_id": "NCT00442702", "title": "A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia" ], "interventions": [ { "name": "Mircera", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 228, "start_date": "2007-09", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2011-12-19", "last_synced_at": "2026-10-02T04:07:28.030Z", "location_count": 11, "location_summary": "Granada Hills, California • Lauderdale Lakes, Florida • Augusta, Georgia + 8 more", "locations": [ { "city": "Granada Hills", "state": "California" }, { "city": "Lauderdale Lakes", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Mineola", "state": "New York" }, { "city": "Orchard Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00442702" }, { "nct_id": "NCT03992066", "title": "Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anemia Associated With Chronic Kidney Disease" ], "interventions": [ { "name": "Vadadustat", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" }, { "name": "Epoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akebia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2019-05-28", "completion_date": "2020-07-15", "has_results": false, "last_update_posted_date": "2020-09-16", "last_synced_at": "2026-10-02T04:07:28.030Z", "location_count": 10, "location_summary": "Escondido, California • Denver, Colorado • Fort Lauderdale, Florida + 7 more", "locations": [ { "city": "Escondido", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03992066" }, { "nct_id": "NCT00058422", "title": "Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "darbepoetin alfa", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "indium In 111 ibritumomab tiuxetan", "type": "RADIATION" }, { "name": "yttrium Y 90 ibritumomab tiuxetan", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "60 Years to 120 Years" }, "enrollment_count": 65, "start_date": "2003-02-10", "completion_date": "2019-11-14", "has_results": true, "last_update_posted_date": "2020-11-12", "last_synced_at": "2026-10-02T04:07:28.030Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00058422" }, { "nct_id": "NCT00416624", "title": "Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anemia", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Precancerous Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "darbepoetin alfa", "type": "DRUG" }, { "name": "epoetin alfa", "type": "DRUG" }, { "name": "fatigue assessment and management", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 239, "start_date": "2007-05", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2017-02-10", "last_synced_at": "2026-10-02T04:07:28.030Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00416624" }, { "nct_id": "NCT00245895", "title": "Study of Aranesp to Treat Anemia in Prostate Cancer Patients.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Anemia" ], "interventions": [ { "name": "Aranesp", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 20, "start_date": "2003-04", "completion_date": "2005-02", "has_results": false, "last_update_posted_date": "2007-11-29", "last_synced_at": "2026-10-02T04:07:28.030Z", "location_count": 2, "location_summary": "Portland, Oregon • Seattle, Washington", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00245895" } ] }